Results 251 to 260 of about 1,116,660 (313)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Engaging communities in recovery: Evaluation of a patient and family advisory committee supporting implementation of the Road to Recovery model of substance use care in British Columbia. [PDF]

Drug Alcohol Depend Rep
Chang D, Nolan S, Morgan J, Ryan A, Barton C, Chippeway R, Hall N, Gregory C, Mundel E, De Wolfe T, Johnson C, Dennis BB.   +11 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain-Related Outcomes Among People With Non-Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial. [PDF]

Drug Alcohol Rev
Lyman K, Choi J, Jutras-Aswad D, Foll BLE, Klaire S, Socias ME.   +5 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Methamphetamine Use and Psychiatric Morbidity in Sri Lanka: Sociodemographic Insights from a Tertiary Care Clinic. [PDF]

Indian J Psychol Med
Galhenage J, Isuru A, Dayabandara M, Hanwella R.   +3 more
europepmc   +1 more source

Working Alliance and Subjective Engagement with a Digital Avatar CBT Platform (RITch^®CBT): Comparing Young Adults with and Without Co-Occurring Substance Use and Depression. [PDF]

Behav Sci (Basel)
Pezzino V, Berbary C, McKinney C, Sangiorgio C, Moriuchi E, Klimczak KS, Cooper RK, Kniffen W, Hareli M, Crane C, Easton CJ.   +10 more
europepmc   +1 more source

Brief intervention can change the trajectory of youth substance use. [PDF]

CMAJ
Charlebois S, Kelly S.
europepmc   +1 more source

COVID-19 pandemic-related stress and substance use behaviors among people with HIV - a mixed method analysis. [PDF]

PLoS One
Rossi SL, Cheng DM, Sereda Y, Truong V, Carroll JJ, Kiriazova T, Lodi S, Michals A, Raj A, Krupitsky E, Lioznov D, Samet JH, Lunze K.   +12 more
europepmc   +1 more source